A Phase 1, Double-blind, Randomized Trial to Evaluate Safety and Immunogenicity of Fluzone® High-Dose Influenza Vaccine When Concomitantly Administered With CD388, a Novel Long-Acting Antiviral Conjugate for the Prevention of Influenza
Latest Information Update: 29 Dec 2025
At a glance
- Drugs CD 388 (Primary) ; Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors Cidara Therapeutics
Most Recent Events
- 29 Dec 2025 New trial record